These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 26740091)
21. Fanconi Anaemia, Childhood Cancer and the Woodward ER; Meyer S Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680915 [TBL] [Abstract][Full Text] [Related]
22. Fanconi anemia with biallelic FANCD1/BRCA2 mutations - Case report of a family with three affected children. Svojgr K; Sumerauer D; Puchmajerova A; Vicha A; Hrusak O; Michalova K; Malis J; Smisek P; Kyncl M; Novotna D; Machackova E; Jencik J; Pycha K; Vaculik M; Kodet R; Stary J Eur J Med Genet; 2016 Mar; 59(3):152-7. PubMed ID: 26657402 [TBL] [Abstract][Full Text] [Related]
23. Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. Meyer S; Tischkowitz M; Chandler K; Gillespie A; Birch JM; Evans DG J Med Genet; 2014 Feb; 51(2):71-5. PubMed ID: 24259538 [TBL] [Abstract][Full Text] [Related]
24. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460 [TBL] [Abstract][Full Text] [Related]
25. The association between FANCD1/BRCA2 mutations and leukaemia. Alter BP Br J Haematol; 2006 May; 133(4):446-8; author reply 448. PubMed ID: 16643458 [No Abstract] [Full Text] [Related]
27. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392 [TBL] [Abstract][Full Text] [Related]
28. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study. Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107 [TBL] [Abstract][Full Text] [Related]
30. Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization. Weber RG; Sommer C; Albert FK; Kiessling M; Cremer T Lab Invest; 1996 Jan; 74(1):108-19. PubMed ID: 8569172 [TBL] [Abstract][Full Text] [Related]
31. Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. Miele E; Mastronuzzi A; Po A; Carai A; Alfano V; Serra A; Colafati GS; Strocchio L; Antonelli M; Buttarelli FR; Zani M; Ferraro S; Buffone A; Vacca A; Screpanti I; Giangaspero F; Giannini G; Locatelli F; Ferretti E Biomark Res; 2015; 3():13. PubMed ID: 26064523 [TBL] [Abstract][Full Text] [Related]
32. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Holtkamp N; Ziegenhagen N; Malzer E; Hartmann C; Giese A; von Deimling A Neuro Oncol; 2007 Jul; 9(3):291-7. PubMed ID: 17504929 [TBL] [Abstract][Full Text] [Related]
33. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604 [TBL] [Abstract][Full Text] [Related]
35. The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17, 19q, TP53 mutation and EGFR amplification) with short clinical course. Jesionek-Kupnicka D; Kulczycka D; Rieske P; Szybka M; Jabłońska J; Potemski P; Kolasa P; Liberski PP; Kordek R Pol J Pathol; 2007; 58(2):79-85. PubMed ID: 17715673 [TBL] [Abstract][Full Text] [Related]
36. Fanconi anemia gene mutations are not involved in sporadic Wilms tumor. Adank MA; Segers H; van Mil SE; van Helsdingen YM; Ameziane N; van den Ouweland AM; Wagner A; Meijers-Heijboer H; Kool M; de Kraker J; Waisfisz Q; van den Heuvel-Eibrink MM Pediatr Blood Cancer; 2010 Oct; 55(4):742-4. PubMed ID: 20589654 [TBL] [Abstract][Full Text] [Related]
37. Discovering gene-environment interactions in glioblastoma through a comprehensive data integration bioinformatics method. Kunkle B; Yoo C; Roy D Neurotoxicology; 2013 Mar; 35():1-14. PubMed ID: 23261424 [TBL] [Abstract][Full Text] [Related]
38. Aurora-A amplification associated with BRCA2 mutation in breast tumours. Bodvarsdottir SK; Hilmarsdottir H; Birgisdottir V; Steinarsdottir M; Jonasson JG; Eyfjord JE Cancer Lett; 2007 Apr; 248(1):96-102. PubMed ID: 16860930 [TBL] [Abstract][Full Text] [Related]
39. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
40. Rapid and convergent evolution in the glioblastoma multiforme genome. Shpak M; Goldberg MM; Cowperthwaite MC Genomics; 2015 Mar; 105(3):159-67. PubMed ID: 25576655 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]